Patents Assigned to Eisai R&D Management Co., Ltd.
  • Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease
    Patent number: 11185554
    Abstract: The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: November 30, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alexander Bukreyev, Fabian Gusovsky, Patrick Younan, Michael Everson
  • High-purity quinoline derivative and method for manufacturing same
    Patent number: 11186547
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: November 30, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
    Patent number: 11179387
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 23, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • EP4 ANTAGONISTS
    Publication number: 20210347779
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: January 5, 2021
    Publication date: November 11, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun ZHENG, Xiaojie ZHU, Hong DU, Maarten POSTEMA, Yimin JIANG, Jing LI, Robert YU, Hyeong-Wook CHOI, Jaemoon LEE, Francis G. FANG, Daniel CUSTAR
  • Method for producing an active hepatocyte growth factor (HGF)
    Patent number: 11168123
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Multikinase inhibitors for use in the treatment of cancer
    Patent number: 11160783
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 2, 2021
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang
  • CRYSTALS OF PYRANODIPYRIDINE COMPOUND
    Publication number: 20210323972
    Abstract: The present invention provides a crystal of the compound represented by formula (I) having applicability as a drug substance of pharmaceuticals.
    Type: Application
    Filed: May 7, 2018
    Publication date: October 21, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Ikuo Kushida, Yoko Ito, Masaaki Matsuda
  • Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
    Patent number: 11147803
    Abstract: There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (I): or a pharmaceutically acceptable salt thereof, and memantine represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 19, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Anti-EphA4 antibody
    Patent number: 11136400
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 5, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
  • C-terminal lysine conjugated immunoglobulins
    Patent number: 11135304
    Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: October 5, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Jared Spidel, Earl Albone
  • Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
    Patent number: 11136335
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 5, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Hyeong-Wook Choi, Atsushi Endo, Francis G. Fang, Dae-Shik Kim
  • Tetrahydropyrazolopyrimidine compounds
    Patent number: 11130758
    Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 28, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
  • MACROCYCLIC COMPOUND AND USES THEREOF
    Publication number: 20210261566
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
    Type: Application
    Filed: February 4, 2021
    Publication date: August 26, 2021
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Methods of treating circadian rhythm sleep disorders
    Patent number: 11096941
    Abstract: Methods of treating irregular sleep-wake rhythm disorder in subjects and compositions for use in the same are disclosed.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 24, 2021
    Assignee: EISAI R&D MANAGEMENT CO.. LTD.
    Inventors: Carsten T. Beuckmann, Margaret Moline, Andrew Satlin
  • FLUORESCENT DYE AND USE THEREOF
    Publication number: 20210255191
    Abstract: Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 19, 2021
    Applicants: Eisai R&D Management Co., Ltd., SYSMEX CORPORATION
    Inventors: Daiki HARA, Takafumi Motoki, Yuji Kazuta, Yoshihiko Norimine, Hiroyuki Amino, Masatoshi Suganuma, Shingo Fujiyama, Kazuto Yamashita, Masaya Okada, Yoichi Nishikawa, Shigeki Iwanaga
  • Method for suppressing bitterness of quinoline derivative
    Patent number: 11090386
    Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 17, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Kentaro Nagane, Yosuke Ueki, Shusuke Sano, Takahisa Sakaguchi
  • Pharmaceutical composition for treating tumor
    Patent number: 11083705
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 10, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Combination therapies for the treatment of breast cancer
    Patent number: 11083722
    Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: August 10, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Craig D. Karr, Manav Korpal, Nathalie Rioux, Peter Gerard Smith
  • SYNTHESIS OF HALICHONDRINS
    Publication number: 20210230177
    Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof.
    Type: Application
    Filed: July 6, 2018
    Publication date: July 29, 2021
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Yanran Ai, Ning Ye, Qiaoyi Wang, Kenzo Yahata, Kentaro Iso, Santhosh Reddy Naini, Shuji Yamashita, Jihoon Lee, Isao Ohashi, Takashi Fukuyama
  • QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION
    Publication number: 20210228722
    Abstract: A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof, and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: wherein, R1 is a hydrogen atom, a C1-6 alkyl group or a C3-8 cycloalkyl group; and R2 is a hydrogen atom or a methoxy group.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Masashi Bando